Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq

Satellos Bioscience ( (TSE:MSCL) ) has shared an announcement.

Satellos Bioscience has priced a cross-border public offering of approximately US$50 million in common shares and pre-funded warrants in Canada and the United States, with 4,455,445 common shares and 495,049 pre-funded warrants to be sold, and an additional 30-day over-allotment option for underwriters to purchase up to 742,574 more shares. The company plans to use the net proceeds primarily to fund research and development, including advancing its lead candidate SAT-3247 from Phase 2 to Phase 3 clinical trials and supporting other early-stage muscle disease programs, while its shares begin trading on Nasdaq under the ticker MSLE. Insider participation by two board members constitutes a related-party transaction under Canadian securities laws but falls below thresholds requiring formal valuation or minority approval and has been approved by the board, underscoring internal confidence in the financing, which is expected to close on February 9, 2026, subject to customary conditions and stock exchange approvals.

The most recent analyst rating on (TSE:MSCL) stock is a Hold with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Spark’s Take on TSE:MSCL Stock

According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.

To see Spark’s full report on TSE:MSCL stock, click here.

More about Satellos Bioscience

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing life-improving medicines for degenerative muscle diseases. Its lead program, SAT-3247, targets muscle dystrophies and is being advanced through mid- to late-stage clinical development, with additional efforts in discovery and pre-clinical programs, including evaluation of other dystrophies. The company’s common shares trade on the Toronto Stock Exchange under the symbol MSCL and have now begun trading on the Nasdaq under the symbol MSLE, reflecting its growing presence in both Canadian and U.S. capital markets.

Average Trading Volume: 28,638

Technical Sentiment Signal: Buy

Current Market Cap: C$258M

For an in-depth examination of MSCL stock, go to TipRanks’ Overview page.